Crimean-Congo Hemorrhagic Fever (CCHF) Market

Market Overview:

The 7 major Crimean-Congo hemorrhagic fever (CCHF) markets reached a value of USD 378.8 Million in 2024. Looking forward, IMARC Group expects the 7MM to reach USD 964.4 Million by 2035, exhibiting a growth rate (CAGR) of 8.89% during 2025-2035.

The Crimean-Congo hemorrhagic fever (CCHF) market has been comprehensively analyzed in IMARC's new report titled "Crimean-Congo Hemorrhagic Fever (CCHF) Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2025-2035". Crimean-Congo haemorrhagic fever (CCHF) is a disease caused by the CCHF virus. It is spread through infected tick bites or direct contact with blood or tissues of infected ticks, individuals, and livestock. Early in the acute infection phase, typical symptoms include nausea, vomiting (which can lead to severe bleeding), diarrhea, stomach discomfort, and a sore throat, followed by rapid mood changes, anxiety, and confusion. After a few days, agitation may be replaced by drowsiness depression, and lassitude, and abdominal pain may be limited to the upper right quadrant, with visible liver enlargement. The onset of symptoms is less than two weeks after exposure. Complications could include liver failure. Diagnosing Crimean-Congo hemorrhagic fever commonly involves a comprehensive clinical assessment and laboratory tests. The healthcare provider may also conduct reverse transcriptase polymerase chain reaction (RT-PCR) to detect the virus, especially in the acute phase of the disease. In some cases, serological tests, such as enzyme-linked immunosorbent assay (ELISA) or immunofluorescence assay might be performed to identify antibodies against the CCHF virus, indicating past or current infection.

The escalating prevalence of the CCHF virus, which transmits through bites from infected ticks of the genus Hyalomma or contact with infected animal blood or tissues, is primarily driving the Crimean-Congo hemorrhagic fever (CCHF) market. In addition to this, the inflating utilization of antiviral medications, like ribavirin, to reduce viral load by interfering with CCHFV RNA synthesis, is also creating a positive outlook for the market. Moreover, the widespread adoption of blood and platelet transfusion on account of its numerous advantages, such as decreased bleeding risk, optimized recovery, and maintained oxygen delivery and tissue perfusion in patients, is further bolstering the market growth. Apart from this, the rising usage of convalescent plasma therapy, since it acts by providing antibodies from recovered patients, potentially aiding in neutralizing the virus and improving outcomes, is acting as another significant growth-inducing factor. Additionally, the emerging popularity of interferon-alpha treatment, which helps to activate the antiviral response by stimulating the expression of interferon-stimulated genes, is expected to drive the Crimean-Congo hemorrhagic fever (CCHF) market during the forecast period.

IMARC Group's new report provides an exhaustive analysis of the Crimean-Congo hemorrhagic fever (CCHF) market in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan. This includes treatment practices, in-market, and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool across the seven major markets. According to the report the United States has the largest patient pool for Crimean-Congo hemorrhagic fever (CCHF) and also represents the largest market for its treatment. Furthermore, the current treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario and unmet medical needs, etc. have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the Crimean-Congo hemorrhagic fever (CCHF) market in any manner.

Drugs:

Crimean-Congo haemorrhagic fever virus vaccines, developed by Auro Vaccines, is using its VesiculoVax platform, which employs engineered vesiculoviruses to deliver CCHF viral antigens. These vectors express the virus's surface glycoproteins authentically, inducing the immune system to produce effective neutralizing antibodies and robust cellular responses. The replication-competent nature of these vectors also enhances innate immune activation, aiming to provide rapid and durable protection against CCHF.

HDT-321 is an investigational vaccine developed by HDT Bio to protect against Crimean-Congo hemorrhagic fever. This vaccine utilizes a self-replicating RNA (repRNA) platform that encodes the CCHF virus nucleoprotein (NP). Upon administration, the repRNA is delivered into host cells using a cationic nanocarrier, leading to the expression of the NP antigen. This expression stimulates the immune system to produce non-neutralizing antibodies targeting the NP. These antibodies confer protection through the intracellular Fc-receptor TRIM21, which facilitates the degradation of antibody-bound viral components, thereby preventing viral replication and infection.

Time Period of the Study

• Base Year: 2024
• Historical Period: 2019-2024
• Market Forecast: 2025-2035

Countries Covered

• United States
• Germany
• France
• United Kingdom
• Italy
• Spain
• Japan

Analysis Covered Across Each Country

• Historical, current, and future epidemiology scenario
• Historical, current, and future performance of the Crimean-Congo hemorrhagic fever (CCHF) market
• Historical, current, and future performance of various therapeutic categories in the market
• Sales of various drugs across the Crimean-Congo hemorrhagic fever (CCHF) market
• Reimbursement scenario in the market
• In-market and pipeline drugs

Competitive Landscape:

This report also provides a detailed analysis of the current Crimean-Congo hemorrhagic fever (CCHF) marketed drugs and late-stage pipeline drugs.

In-Market Drugs

• Drug Overview
• Mechanism of Action
• Regulatory Status
• Clinical Trial Results
• Drug Uptake and Market Performance

Late-Stage Pipeline Drugs

• Drug Overview
• Mechanism of Action
• Regulatory Status
• Clinical Trial Results
• Drug Uptake and Market Performance

*Kindly note that the drugs in the above table only represent a partial list of marketed/pipeline drugs, and the complete list has been provided in the report.

Key Questions Answered in this Report:

Market Insights

• How has the Crimean-Congo hemorrhagic fever (CCHF) market performed so far and how will it perform in the coming years?
• What are the markets shares of various therapeutic segments in 2024 and how are they expected to perform till 2035?
• What was the country-wise size of the Crimean-Congo hemorrhagic fever (CCHF) market across the seven major markets in 2024 and what will it look like in 2035?
• What is the growth rate of the Crimean-Congo hemorrhagic fever (CCHF) market across the seven major markets and what will be the expected growth over the next ten years?
• What are the key unmet needs in the market?

Epidemiology Insights

• What is the number of prevalent cases (2019-2035) of Crimean-Congo hemorrhagic fever (CCHF) across the seven major markets?
• What is the number of prevalent cases (2019-2035) of Crimean-Congo hemorrhagic fever (CCHF) by age across the seven major markets?
• What is the number of prevalent cases (2019-2035) of Crimean-Congo hemorrhagic fever (CCHF) by gender across the seven major markets?
• How many patients are diagnosed (2019-2035) with Crimean-Congo hemorrhagic fever (CCHF) across the seven major markets?
• What is the size of the Crimean-Congo hemorrhagic fever (CCHF) patient pool (2019-2024) across the seven major markets?
• What would be the forecasted patient pool (2025-2035) across the seven major markets?
• What are the key factors driving the epidemiological trend of Crimean-Congo hemorrhagic fever (CCHF)?
• What will be the growth rate of patients across the seven major markets?

Crimean-Congo Hemorrhagic Fever (CCHF): Current Treatment Scenario, Marketed Drugs and Emerging Therapies

• What are the current marketed drugs and what are their market performance?
• What are the key pipeline drugs and how are they expected to perform in the coming years?
• How safe are the current marketed drugs and what are their efficacies?
• How safe are the late-stage pipeline drugs and what are their efficacies?
• What are the current treatment guidelines for Crimean-Congo hemorrhagic fever (CCHF) drugs across the seven major markets?
• Who are the key companies in the market and what are their market shares?
• What are the key mergers and acquisitions, licensing activities, collaborations, etc. related to the Crimean-Congo hemorrhagic fever (CCHF) market?
• What are the key regulatory events related to the Crimean-Congo hemorrhagic fever (CCHF) market?
• What is the structure of clinical trial landscape by status related to the Crimean-Congo hemorrhagic fever (CCHF) market?
• What is the structure of clinical trial landscape by phase related to the Crimean-Congo hemorrhagic fever (CCHF) market?
• What is the structure of clinical trial landscape by route of administration related to the Crimean-Congo hemorrhagic fever (CCHF) market?